Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 2, 2023
Daily News
February 2, 2023
- MHLW Scratching Head over High-Price Drug Issue, Lecanemab in Mind: Bureau Chief
February 2, 2023
- Tarlige Snatches Pole Position from Twymeeg in GP Promotion Ranking in December: Intage
February 2, 2023
- Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica Now in Line for Approval
February 2, 2023
- Hemlibra Approved in Europe for Moderate Hemophilia A: Roche/Chugai
February 2, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…